Indaptus Therapeutics reported a net loss of approximately $1.8 million for the second quarter ended June 30, 2026, compared to $5.2 million in the prior year period. The company completed a private placement on June 17, 2026, issuing 20,000,000 shares at $0.60 per share for gross proceeds of approximately $12.0 million. This financing increased cash and short-term investments to $11.6 million as of June 30, 2026. Indaptus discontinued enrollment in its Decoy20 clinical study and has no active clinical development programs while evaluating strategic alternatives. The company also initiated a research collaboration in neurological disorders and sleep. At its August 10, 2026 annual meeting, shareholders elected three directors and approved the 2026 Equity Incentive Plan. Indaptus Therapeutics is a biotechnology company dedicated to immunotherapy research.
